Oncotarget

Research Papers:

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion

Claire Henry _, Estelle Llamosas, Alexandra Knipprath-Meszaros, Andreas Schoetzau, Ellen Obermann, Maya Fuenfschilling, Rosemarie Caduff, Daniel Fink, Neville Hacker, Robyn Ward, Viola Heinzelmann-Schwarz and Caroline Ford

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:40310-40326. https://doi.org/10.18632/oncotarget.5643

Metrics: PDF 3477 views  |   HTML 4122 views  |   ?  


Abstract

Claire Henry1, Estelle Llamosas1, Alexandra Knipprath-Meszaros2, Andreas Schoetzau2, Ellen Obermann3, Maya Fuenfschilling3, Rosemarie Caduff4, Daniel Fink5, Neville Hacker6, Robyn Ward7, Viola Heinzelmann-Schwarz2, Caroline Ford1

1Metastasis Research Group, Adult Cancer Program, Lowy Cancer Research Centre and Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, New South Wales, Australia

2Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, University of Basel, Basel, Switzerland

3Department of Pathology, University Hospital Basel, University of Basel, Basel, Switzerland

4Department of Pathology, University Hospital Zurich, Zurich, Switzerland

5Department of Gynecology, University Hospital Zurich, Zurich, Switzerland

6Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia

7Department of Research, The University of Queensland, Brisbane, Queensland, Australia

Correspondence to:

Caroline Ford, e-mail: [email protected]

Keywords: ROR2, ROR1, Wnt signalling, epithelial ovarian cancer, metastasis

Received: May 21, 2015     Accepted: October 08, 2015     Published: October 20, 2015

ABSTRACT

AIM: In recent years, the Wnt signalling pathway has been implicated in epithelial ovarian cancer and its members have potential as diagnostic, prognostic and therapeutic targets. Here we investigated the role of two Wnt receptor tyrosine kinases (RTKs), ROR1 and ROR2, and their putative ligand, Wnt5a, in ovarian cancer.

METHODS: Immunohistochemistry for ROR2 was performed in a large patient cohort, including benign controls, borderline tumours and epithelial ovarian cancer. In addition, siRNA was used to silence ROR1, ROR2 and Wnt5a individually, and together, in two ovarian cancer cell lines, and the effects on cell proliferation, adhesion, migration and invasion were measured.

RESULTS: ROR2 expression is significantly increased in ovarian cancer patients compared to patients with benign disease. In vitro assays showed that silencing either receptor inhibits ovarian cancer cell migration and invasion, and concurrently silencing both receptors has an even stronger inhibitory effect on proliferation, migration and invasion.

CONCLUSIONS: ROR2 expression is increased in epithelial ovarian cancer, and silencing ROR2 and its sister receptor ROR1 has a strong inhibitory effect on the ability of ovarian cancer cells to proliferate, migrate and invade through an extracellular matrix.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5643